Bio-Techne (TECH) Liabilities from Discontinued Operations (2023 - 2024)
Bio-Techne (TECH) posted quarterly Liabilities from Discontinued Operations of 689000.0 for Q1 2024, down 56.75% quarter-over-quarter from 1593000.0 in Q4 2023.
Powered by 
Analysis
Bio-Techne (TECH) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends
Bio-Techne's Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 689000.0 for Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn |